Abstract:The authors show that GM1 induced conformational change of presenilin 1 (the catalytic subunit of γ‐secretase) into a preactivated state that is ready to accommodate the substrate, thus promoting γ‐secretase cleavage of APP without affecting other substrates. At last, reducing GM1 levels significantly decreases the amyloid plaque deposition and cognitive dysfunction via reducing γ‐secretase activity. A hallmark of Alzheimer's disease (AD) is the senile plaque, which contains β‐amyloid peptides (Aβ). Ganglioside GM1 is the most common brain ganglioside. However, the mechanism of GM1 in modulating Aβ processing is rarely known. Aβ levels are detected by using Immunohistochemistry (IHC) and enzyme‐linked immune‐sorbent assay (ELISA). Cryo‐electron microscopy (Cryo‐EM) is used to determine the structure of γ‐secretase supplemented with GM1. The levels of the cleavage of amyloid precursor protein (APP)/Cadherin/Notch1 are detected using Western blot analysis. Y maze, object translocation, and Barnes maze are performed to evaluate cognitive functions. GM1 leads to conformational change of γ‐secretase structure and specifically accelerates γ‐secretase cleavage of APP without affecting other substrates including Notch1, potentially through its interaction with the N‐terminal fragment of presenilin 1 (PS1). Reduction of GM1 levels decreases amyloid plaque deposition and improves cognitive dysfunction. This study reveals the mechanism of GM1 in Aβ generation and provides the evidence that decreasing GM1 levels represents a potential strategy in AD treatment. These results provide insights into the detailed mechanism of the effect of GM1 on PS1, representing a step toward the characterization of its novel role in the modulation of γ‐secretase activity and the pathogenesis of AD.

A GPCR/secretase Complex Regulates Β- and Γ-Secretase Specificity for Aβ Production and Contributes to AD Pathogenesis

Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease

Receptor Tyrosine Kinases Positively Regulate BACE Activity and Amyloid-β Production Through Enhancing BACE Internalization

Regulatory Role Of Golgi Brefeldin A Resistance Factor-1 In Amyloid Precursor Protein Trafficking, Cleavage And A Beta Formation

Secretases Related to Amyloid Precursor Protein Processing

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Regulation Of Beta Cleavage Of Amyloid Precursor Protein

C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Regulation of β cleavage of amyloid precursor protein

Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ-secretase function in generating Alzheimer-causing Aβ peptides

Lys203 and Lys382 Are Essential for the Proteasomal Degradation of BACE1

Secretase inhibitors and modulators for Alzheimer’s disease treatment

Activation of Β2-Adrenergic Receptor Stimulates Γ-Secretase Activity and Accelerates Amyloid Plaque Formation

Preferential Regulation of Γ‐Secretase‐Mediated Cleavage of APP by Ganglioside GM1 Reveals a Potential Therapeutic Target for Alzheimer's Disease

Alpha-secretase inhibition impairs Group I metabotropic glutamate receptor-mediated protein synthesis, long-term potentiation and long-term depression

Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators

Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes

Inhibition of Gamma-Secretase Activity Reduces A Beta Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer'S Disease

Beta-Amyloid Redirects Norepinephrine Signaling To Activate The Pathogenic Gsk3 Beta/Tau Cascade

APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ

Β-Amyloid Redirects Norepinephrine Signaling to Activate the Pathogenic GSK3β/tau Cascade.